A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data
- Authors
- Cheema, Parneet; Cho, Byoung Chul; Freitas, Helano; Provencio, Mariano; Chen, Yuh Min; Kim, Sang-We; Wu, Yi-Long; Passaro, Antonio; Martin, Claudio; Tiseo, Marcello; Chang, Gee-Chen; Park, Keunchil; Solomon, Benjamin; Burghuber, Otto; Laskin, Janessa; Wang, Ziping; Lee, Sung Yong; Hu, Yanping; Vansteenkiste, Johan; Zhang, He-long; Hanrahan, Emer; Geldart, Thomas; Taylor, Rosemary; Servidio, Leslie; Li, Jingyi; de Marinis, Filippo
- Issue Date
- Jan-2023
- Publisher
- Future Medicine Ltd.
- Keywords
- EGFR; non-small-cell lung cancer; osimertinib; real world; T790M
- Citation
- Future Oncology
- Indexed
- SCIE
SCOPUS
- Journal Title
- Future Oncology
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/62451
- DOI
- 10.2217/fon-2022-0919
- ISSN
- 1479-6694
1744-8301
- Abstract
- Aim
Report the final analysis from ASTRIS, the largest real-world study of second-/later-line osimertinib in advanced/metastatic EGFR T790M non-small-cell lung cancer (NSCLC).
Methods
Patients with advanced/metastatic EGFR T790M NSCLC and prior EGFR-TKI treatment, received once-daily osimertinib 80 mg. Primary end point: overall survival (OS); secondary end points: progression-free survival (PFS), time-to-treatment discontinuation (TTD) and response rate. Safety was also recorded.
Results
In 3014 patients, median OS: 22.8 months (21.6–23.8), median PFS: 11.1 months (11.0–12.0), median TTD: 13.5 months (12.6–13.9), and response rate: 57.3% (55.5–59.2). All end points reported with 95% CIs. Numerically longer median OS was observed in patients with baseline WHO performance status <2 versus 2 (24.0 vs 11.1 months) and those without versus with brain/leptomeningeal metastases (25.4 vs 18.0 months). No new safety signals were identified.
Conclusion
Second-/later-line osimertinib demonstrated real-world clinical benefit and safety in advanced/metastatic EGFR T790M NSCLC.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Pulmonary, Allergy, and Critical Care Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.